Catalogue Number: AB04906-23.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | TNF-α; TNFα; TNF; TNFA; TNFSF; Tumor necrosis factor; Cachectin; TNFalpha; TNF-alpha; Tumor necrosis factor ligand superfamily member 2; TNF-a; TNFa; CDP870; PHA-738144; CIMZIA |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | Rabbit |
| Clone: | hTNF40 (Certolizumab) |
| Isotype: | IgG |
| Immunogen: | The original antibody is a monovalent Fab fragment of a humanized anti-TNFα antibody and lacks the Fc region. Further, the hinge region is attached to two cross-linked chains of a 20-kDa polyethylene glycol (PEG). |
| Application: | InVitroA, InVivoA, Crstapy |
TNF
7124
P01375
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques.
The PEGylated Fab fragment of the antibody has been approved by the FDA as a biologic against TNFα. The original format of the antibody was used for in vitro and in vivo studies, where it showed to neutralize the activity of TNFα. Further, the antibody was effective and well tolerated by patients with RA (Choy et al, 2002; PMID: 12364632). The structure of Fab fragment of the antibody in complex with human TNFα was determined. The binding affinity of the Fab fragment to TNFα was measured by surface plasmon resonance (Kd= 0.2 pM) (Lee et al., 2017; PMID: 28124979). The specificity of the original format of the antibody was confirmed by ELISA analysis (US7012135). The original format of the antibody bound and neutralised both soluble and membrane-bound forms of TNFα. The pharmacokinetic properties of the PEGylate Fab fragments in vivo resulted in a half-life of 14 days. Isothermal titration calorimetry data showed that the original format of the antibody bound to 2.9 monomers in a TNFα trimer at saturation. The antibody was employed in in vivo studies in rats, primates and humans. Several clinical trials have also been conducted to examine the efficacy and tolerability of the original format of the antibody in patients with CD, RA and psoriasis (Filipovica et al., 2009).